Experimental Vaccine For Chikungunya Passes First Test | WAMU 88.5 - American University Radio

NPR : News

Experimental Vaccine For Chikungunya Passes First Test

Scientists have taken the first steps to developing a vaccine for chikungunya — an emerging mosquito-borne virus that has infected more than a half million people in the Western Hemisphere this year. About 600 Americans have brought the virus to 43 states.

The study was small. Only 25 people were given the experimental vaccine. But the findings are promising. They demonstrate that the vaccine is safe and that it triggers a strong response from the immune system, scientists reported Friday in the Lancet journal.

Until last year, chikungunya was found only in parts of Africa and Asia. Then in December, the virus started circulating on the island of St. Martin in the Caribbean.

From there, chikungunya spread like wildfire. It hopped from island to island in the Caribbean and spilled over into Central America and parts of South America. By July, chikungunya had found its way to Florida. At least four people have caught the virus in Florida. And the state has recorded 138 imported cases. New York state has the second largest number of imported cases, 96.

Chikungunya usually isn't fatal. But it causes a high fever, headache, nausea and extreme joint pain — which can linger for months. And there's no cure or vaccine.

To start filling in that second gap, a team of researchers at the National Institutes of Allergy and Infectious Diseases in Bethesda designed a vaccine using virus-like particles, a new technology. Synthetic particles carry proteins found on the virus's outside shell.

The particles don't contain any of chikungunya's genes. So they're not infectious. But the immune system doesn't realize that. When Dr. Julie Ledgerwood and her colleagues injected the virus-like particles into the muscles of volunteers, their immune systems created antibodies that can stop the virus from infecting cells.

After three injections, the participants had chikungunya antibodies in their blood at concentrations similar to those found in people who had fought off the viral infection. And these antibodies stuck around in the volunteers' blood for at least six months. Those findings suggest that the vaccine could give long-term protection.

But Ledgerwood and her team won't know if that's true until they test the vaccine in more people and see how effective it is at stopping an infection.

Overall, the experimental vaccine was well tolerated by the volunteers. Nine out of the 25 developed tenderness where the shot was given. And ten volunteers reported tiredness, nausea or headaches after the vaccine. But in general, the shot was safe.

This experimental vaccine isn't the first for chikungunya. Back in the 1980s, a team at the U.S. Army Medical Research Institute of Infectious Diseases created a vaccine with a live, weakened version of the virus. That vaccine completed a phase 2 clinical trial. But scientists halted its development because there wasn't enough funding.

Copyright 2014 NPR. To see more, visit http://www.npr.org/.

NPR

David Oyelowo On Acting, His Royal Roots And The One Role He Won't Take

The British-born Nigerian actor talks about playing an American veteran in Nightingale, the reasons he stays in character for weeks at a time and his aversion to playing "the black best friend."
NPR

Bugs: Not What's For Dinner — Until They're Tastier, Maybe

A U.K. researcher says the environmental argument for eating bugs isn't working on its own. She says chefs and policymakers must "make insect dishes appeal as food, not just a way to save the planet."
NPR

5 Things You Should Know About George Pataki

For most voters, the name George Pataki might not ring a bell. But he was the last Republican elected to major statewide office in New York in more than 20 years. And he's running for president.
NPR

Smartphones Are So Smart They Can Now Test Your Vision

In a new study, an easy-to-use app did just as good a job as the machines in an eye doctor's office. That's a boon for people in low-income countries — and really for anyone with vision issues.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.